Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InspireMD's MGuard Coronary:

This article was originally published in Clinica

Executive Summary

Israeli firm InspireMD has received permission to CE mark its MGuard Coronary stent for the treatment of patients with coronary artery diseases. MGuard Coronary combines a coronary stent with an embolic protection device - an ultra-thin polymer mesh sleeve wrapped around the stent, designed to provide embolic shower protection during and after stenting. The sleeve expands when the stent is deployed without affecting the structure of the stent, and diffuses stent pressure on the vessel wall, and thereby may reduce injury and the likelihood of restenosis. The technology may also provide a drug delivery mechanism for next-generation drug-eluting stents. The Tel Aviv-based company claims it has "already received pre-launch orders valued at over $1.5m."

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel